Opinion|Videos|December 7, 2023
A Patient’s Experience With an RCC Diagnosis
Author(s)Thomas E. Hutson, DO, PharmD, Kacie Ellis, RN
Mr. Cesar Fuentes had a kidney tumor surgically removed; lymph node and bone metastases years later led to immune and targeted therapy which have provided significant tumor shrinkage and generally mild, manageable side effects.
Advertisement
Episodes in this series
Advertisement
Related to this article
“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
2
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
3
Young Adults With Lung Cancer Often Fall Outside Screening Guidelines
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5